

Awards and Appointments

Nottingham's clinical oncology team win national award

A research team in Clinical Oncology at The University of Nottingham has been awarded 'Research Team of the Year 2012' by Breast Cancer Campaign. Associate Professor Stewart Martin and his team received the award for their work in advancing knowledge of breast cancer via their scientific publications. Breast Cancer Campaign has a pioneering approach to breast cancer research and funds research projects that have the greatest potential to save and improve lives of women with breast cancer.

Dr Martin said: "This is a very significant accolade that we are very pleased to accept. Having attended a previous Breast Cancer Campaign awards ceremony I

found listening to, and chatting with, all the fundraisers, breast cancer survivors and their families and friends both humbling and inspirational."

Dr Martin and his team have received a number of research grants which have contributed to a wide range of life-saving research. Their most recent discovery is that a protein could help to predict the chances of survival for women with the most limited treatment options. This could lead to the development of a new test in the next five to 10 years, which could predict survival outcomes for women with triple negative breast cancer. These types of breast cancer affect up to 8,000 women each year in the UK. ■



Professor Stewart Martin and Baroness Delyth Morgan, chief executive of Breast Cancer Campaign.

Leading Queen's scientist recognised with international cancer award

Leading Queen's University Belfast scientist, Professor Paddy Johnston, has been named as recipient of the 2013 Bob Pinedo Cancer Care Prize. The award recognises Prof. Johnston's pioneering work in translating discovery science for the benefit of cancer patients.

This year's Pinedo Prize of \$50,000 will be presented at the Society for Translational Oncology's Fourth Annual meeting in Amsterdam on the 1st of October, 2013.

In 2012, Professor Johnston was honoured to accept a Diamond Jubilee Queen's Anniversary Prize awarded by Her Majesty, The Queen, for The Queen's University Belfast-led Comprehensive Cancer Centre and its achievement in reducing cancer mortality rates over the last decade. This significant improvement in cancer outcomes, underpinned by best quality care and innovative research, is a direct result of Prof. Johnston's philosophy of placing the cancer patient at the centre of the cancer care and research agenda.

Speaking about the award, Prof. Johnston said: "I am delighted and humbled to have been awarded The Pinedo Prize. It is a great honour to have my work and that of my research team recognised by the international cancer research community in this way." ■

Clinical Nurse Specialist wins Innovation and Excellence Award in Cancer Nursing

Maureen Morris, Northland DHB Clinical Nurse Specialist (CNS) Colorectal, was recently awarded the Innovation and Excellence Award in Cancer Nursing. Maureen is the first recipient of the NZ Nurses Organisation's Cancer Nurses Section award which honours 'Innovation and Nursing excellence'. "This award is a wonderful honour for Maureen and due recognition of her commitment to nursing and to cancer care", said Margareth Broodkoorn, Northland DHB Director of Nursing and Midwifery. "I have had the privilege of working with Maureen in my team, she is a joy to work with". Nominated by her Registered Nurse peer Deborah Schlatter, Maureen exhibits excellence by providing clinical leadership based on in-depth knowledge and experience gained from 25 years of working in many aspects of cancer nursing. "I have worked with Maureen for three years here in Whangarei where she has excelled in her capacity as the Colorectal Clinical Nurse Specialist", offered Deborah. "I am honoured to have been acknowledged for my work and remain committed that cancer nursing must be patient centred and evidence based", Maureen said. "If nursing is truly valued and it is delivered in an infrastructure which is supportive we can ensure that we are really making a difference in the experience for patients and families". ■



Left to right Wendy Thomas Chair NZNO Cancer Nurses Section, Maureen Morris and Sue Wood Director of Nursing, Cancer.

Professor Sir David Lane is the new Scientific Director of the Ludwig Institute

Professor Sir David Lane has been appointed Scientific Director of the Ludwig Institute for Cancer Research. He will lead the Institute's global cancer research effort, expanding interaction among Ludwig's network and representing its science and scientists to the broader cancer community.

He brings years of dedicated leadership experience, having directed scientific programs at Imperial College, ICRF Laboratories at Clare Hall, helped establish the Cancer Research Campaign (CRC) laboratories at the University of Dundee in Scotland, served as Cancer UK's first Chief Scientist, and founded the Cyclacel biotechnology company.

"I'm really delighted to join the Ludwig Institute as its Scientific Director," said Lane. "I've gotten to know Ludwig very well as a member of its Scientific Advisory Committee and also of the Board. I know what a tremendous opportunity it offers in terms of fostering breakthrough cancer research." As an independently funded, international network of scientists with a 40-year legacy of pioneering cancer discoveries, David stresses that Ludwig has a 'unique ability' to carry its research all the way from bench to bedside. And he adds, "It's an exciting time to join the Ludwig community and help maximise the potential of its discoveries."

Through both his leadership and research, he has made an incredible impact on the fight against cancer. Finally he urges, "We all need to keep the faith. Science is hard and long, and what we've achieved in the way of improving cancer patient outcomes over the past four decades is just tremendous; it's important that society understands and supports science because it is what gives us hope for a better future." ■

